vTv Therapeutics (VTVT) Insider Anne Phillips Buys $210K of Stock
Anne Phillips purchased VTVT shares, marking insider interest in the stock.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anne Phillips bought 6,000 shares of vTv Therapeutics Inc. ($VTVT) at an average price of $35.08, worth about $210,480, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $VTVT is down 1.5% after 1 week, down 11.6% after 1 month and down 24.3% to date (from the $35.08 close on Jun 26, 2026).
VTVT
vTv Therapeutics Inc.
Key Points
- On June 26, 2026, Anne Phillips purchased 6,000 shares of VTVT at an average price of $35.08, totaling $210,480.
- Shares of VTVT traded near $36.27 on Tuesday, with analysts maintaining a positive outlook and price targets up to $67.
- Several insiders, including Anne Phillips, increased their holdings in VTVT, indicating continued confidence in the company's prospects.
Get $VTVT trade alerts by text
We text you when insiders, Congress or big funds trade $VTVT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated vTv Therapeutics Inc. alert may contain errors. Disclosures
Anne Phillips, an insider, purchased 6,000 shares of VTVT on June 26, 2026. The shares were bought at an average price of $35.08, resulting in a total transaction value of $210,480. This move reflects insider interest in the company.
Other Institutional Activity in VTVT
Samsara Biocapital, LLC maintained its holdings in VTVT with 298,496 shares worth about $11.8 million. FMR LLC trimmed its position by 8,465 shares, holding 260,391 shares valued at approximately $10.3 million, marking a 3.1% decrease. Millennium Management LLC opened a new position, acquiring 206,288 shares valued at $8.2 million. Meanwhile, Trails Edge Capital Partners, LP reduced its stake by 91,422 shares, ending with 139,578 shares worth about $5.5 million, a 39.6% decrease.
vTv Therapeutics Inc. Stock Up 14.1%
Shares of VTVT traded around $36.27 on Tuesday. The stock has been active among analysts, with several firms maintaining or initiating buy ratings. The stock's 52-week high and low are not specified, but the recent analyst activity suggests a positive outlook.
Insider Buying and Selling at vTv Therapeutics Inc.
In addition to Anne Phillips, several other insiders purchased 6,000 shares each at $35.08 on June 26, 2026. This includes Srinivas Akkaraju, Fahed Al-Marzooqi, Daniel Spiegelman, and Paul Sekhri, who is the President, CEO, and Executive Chairperson, who also made a significant purchase of 140,000 shares at $36.92 earlier in the year.
Analysts Set New Price Targets
On March 12, 2026, Evercore ISI Group initiated coverage of VTVT with a buy rating and a $44 price target. BTIG maintained its buy rating with a $49 target on January 27, 2026. Roth Capital also initiated a buy rating with a $58 target on January 23, 2026. Analysts overall have been positive, with a consensus buy recommendation and price targets ranging up to $67.
Bottom Line
Anne Phillips' purchase of VTVT shares signifies a strong insider interest in the company. The stock has seen positive analyst coverage with high price targets, indicating confidence in its future performance. Insider transactions like these provide valuable insights into the company's prospects, though they reflect past actions and not current positions.
Related Filing Alerts
Source: Anne Phillips's Form 4 filing on $VTVT (Jun 26, 2026). Find the original filing: VTVT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts